The promise of mRNA therapeutics in producing the first regenerative treatment for SUI
Article by Dr Roger Dmochowski, Professor of Urology & Advisory Board Member of Versameb
Tag Archive for: mRNA
Versameb CEO Klaas Zuideveld to Present at the RNA Leaders World Congress
Presentation demonstrates lead therapeutic candidate VMB-100 has the potential to address the unmet medical needs of patients suffering from Stress Urinary Incontinence Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its leadership team will be attending the RNA Leaders World Congress, taking place on the 16-17th […]
Touchlight and Versameb announce GMP manufacturing supply agreement
Versameb moves forward with its lead asset towards clinical development with an Innovative synthetic doggybone DNA technology which increases quality and yield of mRNA therapeutics production Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a development and manufacturing pipeline agreement with Versameb AG, an innovative pre-clinical stage […]
Versameb appoints world leading experts in urology to Advisory Board
Appointment of experts to support development of lead candidate VMB-100, an RNA-based therapy for Stress Urinary Incontinence Versameb AG (“Versameb”), focused on discovering and developing innovative RNA-based drugs, today announces the formation of an Advisory Board comprised of industry leaders in urology. These include Professor Roger Dmochowski of Vanderbilt University, Professor Margot Damaser of the […]
Versameb to present at the Female Pelvic Medicine and Urogenital Reconstruction 2022 Winter Meeting
Data demonstrates first-in-class potential as a regenerative treatment of Stress Urinary Incontinence Treatment results in muscle regeneration with restored functionality in pre-clinical models Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its Chief Scientific Officer, Friedrich Metzger will be presenting data on the Company’s mRNA […]
